Introduction
2019 was a good year for lupus patients, as multiple companies reported positive results of their late-stage clinical trials. However, this is not necessarily positive news for Kezar Life Sciences (KZR). The company is currently developing a cure for rare inflammatory diseases, such as lupus, polymyositis, and dermatomyositis. Despite having a new drug candidate with an interesting mechanism, it would still have to compete against other established players in this field. That is the reason why we focused our research on the opportunity for Polymyositis and dermatomyositis.
Polymyositis and dermatomyositis
Both of